Arsenal Biosciences trims most of its workforce as it shifts focus to in vivo CAR T therapy

Arsenal Biosciences announced another round of staff reductions, letting go of the majority of its employees.

This follows a previous reduction about a year ago that cut roughly half of its workforce.

The cuts are tied to a strategic pivot toward developing in vivo CAR T therapies, moving away from its earlier approach.

The company did not disclose exact numbers or a timeline for the restructuring.